Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4418
- Book/Share 8.5941
- PB 5.264
- Debt/Equity 2.9211
- CurrentRatio 1.2068
- ROIC 0.1328
- MktCap 91798156294.0
- FreeCF/Share 7.1636
- PFCF 6.297
- PE 18.1776
- Debt/Assets 0.5379
- DivYield 0.0545
- ROE 0.2957
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
3 Pharma Stocks Getting an Intraday Trump Bump
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.
Read More
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV Dogs—ET, MPLX, YRD, VZ, BMY, BBVA, and MFC—are highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September 2026, with Energy Transfer (ET) leading at 35.43%.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Read More
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Read More
Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM EDT Company Participants Lynelle Hoch - President of Cell Therapy Organization Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
Read More
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Published: September 17, 2025 by: Reuters
Sentiment: Positive
Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.
Read More
Bristol Myers to sell 60% stake in China joint venture
Published: September 17, 2025 by: Reuters
Sentiment: Neutral
U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
Read More
Meet 16 Ideal "Safer" September Dividend Dogs Of The S&P500
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of high yield and low price, following the O'Higgins 'Dogs of the Dow' strategy.
Read More
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
Read More
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
Published: September 08, 2025 by: Benzinga
Sentiment: Positive
BioNTech SE BNTX and Bristol Myers Squibb Co BMY shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).
Read More
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
Published: September 08, 2025 by: Reuters
Sentiment: Positive
A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday.
Read More
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb continues to trade below $50, creating a divergence with strong performance from its oncology and cardiovascular franchises. So, sales of its "diamond" in the treatment of non-Hodgkin lymphoma called Breyanzi reached $344 million in Q2 2025, increasing by more than 100% year-on-year. Moreover, Bristol-Myers may expand its label on December 5, 2025, and become the first CAR T-cell therapy in the treatment of relapsed/refractory marginal zone lymphoma.
Read More
Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Negative
Bristol-Myers Squibb stock remains undervalued, even though it faces significant LOE risks through 2028. BMY's growth portfolio is gaining credence, helping to mitigate the risks due to the decline in its legacy segment. Notably, BMY's robust profitability and a sector-leading dividend yield help to secure buy-in from income investors with the patience to ride out the near-term turbulence.
Read More
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
Read More
7 Big Yields From The Beat-Up Healthcare Sector
Published: September 01, 2025 by: Forbes
Sentiment: Neutral
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
Read More
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
Read More
Final Trades: ServiceNow, Bristol Myers and Live Nation
Published: August 21, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
First Breakthrough Therapy Designation in the U.S. for SystImmune and Bristol Myers Squibb's Izalontamab brengitecan (Iza-bren) based on data from the BL-B01D1-101 (CN), BL-B01D1-203 (CN), and BL-B01D1-LUNG-101 (U.S.,/EU) studies REDMOND, Wash. and PRINCETON, N.J.
Read More
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
Read More
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising over 50% of its overall revenues, with further expansion likely thanks to its intensified R&D, partnerships, and M&A efforts. BMY's discounted valuations present a deep-value buying opportunity, with patient investors well rewarded with rich dividend yields, pending growth acceleration.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100